Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144976
Status:
COMPLETED
Last Update Posted:
2015-03-27
First Post:
2005-09-02
Brief Title:
Study of Biological Effect of Tarceva OSI-774 for Patients Stricken by ENT Epidermoid Carcinoma
Sponsor:
Institut Claudius Regaud
Organization:
Institut Claudius Regaud
Study Overview
Official Title:
Pilot Study Without Direct Individual Benefice of Biological Effect of Tarceva OSI-774 at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the biological effect of Tarceva OSI-774 from an inhibition of EGF tumor receptor tyrosine kinase activitys point of view for patients who are carriers of head and neck epidermoid carcinoma
Detailed Description:
Patients will receive Tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None